Reskuin en es it fr


Reskuin Nombres de marca, Reskuin Analogos

Reskuin Marca los nombres de mezcla

  • No information avaliable
  • Reskuin Formula quimica


    Reskuin RX enlace

    Reskuin FDA hoja

    Reskuin FDA

    Reskuin MSDS (hoja de seguridad de materiales)

    Reskuin Sintesis de referencia

    Mitscher, Lester A. et al;. J.Med.Chem;. 30, 12, 2283 hasta 2286 (1987)

    Reskuin Peso molecular

    740.751 g/mol

    Reskuin Punto de fusion

    No information avaliable

    Reskuin H2O Solubilidad


    Reskuin Estado


    Reskuin LogP


    Reskuin Formas de dosificacion

    Tableta, líquido, la solución

    Reskuin Indicacion

    Para el tratamiento de la conjuntivitis bacteriana causada por cepas susceptibles de los siguientes organismos: Corynebacterium spp, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (grupos C / F / G), estreptococos del grupo viridans, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

    Reskuin Farmacologia

    Levofloxacina, una fluoroquinolona antiinfeccioso, es ópticamente activos L-isómero de ofloxacino. Levofloxacino se usa para tratar la conjuntivitis bacteriana, sinusitis, bronquitis crónica, neumonía adquirida en la comunidad y neumonía causada por cepas resistentes a penicilina de Streptococcus pneumoniae, infecciones de la piel y estructura de la piel, infecciones complicadas del tracto urinario y pielonefritis aguda.

    Reskuin Absorcion

    La absorción de ofloxacino tras dosis únicas o múltiples de 200 a 400 mg es predecible, y la cantidad de fármaco absorbido aumenta proporcionalmente con la dosis.

    Reskuin Toxicidad

    Los efectos secundarios incluyen desorientación, mareos, somnolencia, sofocos y frío, náuseas, dificultad en el habla, la hinchazón y entumecimiento en la cara

    Reskuin Informacion de Pacientes


    While taking ofloxacin patient should be advised to:

    to drink fluids liberally;

    that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

    that ofloxacin can be taken without regard to meals;

    that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

    to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

    that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

    to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

    that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

    that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

    Reskuin Organismos afectados

    Bacterias entéricas y otras eubacterias